Practical implication
Update all internal and external communications, labels, and marketing materials to reflect the new product name, Svariya, instead of Rivaroxaban Koanaa.
Svariya, an anticoagulant medication, has been authorized in the EU under its new name following studies confirming its bioequivalence to the reference medicine, Xarelto. The change in name requires updates to promotional and regulatory materials.
What changed: Label change required for the product previously known as Rivaroxaban Koanaa to its new designation, Svariya.
Why it matters: This labeling update is crucial for ensuring accurate information dissemination to healthcare professionals and patients about the medication, which affects its safe and effective use.
Practical implication: Update all internal and external communications, labels, and marketing materials to reflect the new product name, Svariya, instead of Rivaroxaban Koanaa.
View original source
- Source: EMA - What's new
- Published at source: 2026-08-25T12:22:00.000Z
- Discovered by monitor: 2026-08-26T22:34:55.030Z
Published from the regulator source ingestion pipeline after PV impact triage.
